Asana Biosciences, LLC

Jubilant Epipad LLC

Ansana Biosciences, LLC

Gurulingappa Hallur

Aranapakam Mudumbai Venkatesan

Roger Astbury Smith

Scott Kevin Thompson

Raghava Reddy Kethiri

Chandrika Mulakala

Sanjeeva P Reddy

Purushottam M Dewang

Sridharan Rajagopal

Athisayamani Jeyaraj Duraiswamy

Buchi Reddy Purra

Ramesh Mullangi

Mohd Zainuddin

Rajendra Kristam

Nvsk Rao

N V S K Rao

Heterocyclic compounds of Formula (I) are described herein along with their stereoisomers and pharmaceutically acceptable salts thereof. The compounds described herein, their stereoisomers, and pharmaceutically acceptable salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis.

Heterocyclic compounds as pad inhibitors

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and Rto Rare defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described. 

Imidazo-pyridine compounds as PAD inhibitors

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and Rto Rare defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer. 

Growing community of inventors

Bengaluru, India

Gurulingappa Hallur